BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ebbers HC, Fehrmann B, Ottosen M, Hvorslev N, Høier P, Hwang JW, Chung J, Lim HT, Lee S, Hong J, Rezk MF. Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. BioDrugs 2020;34:225-33. [PMID: 31925703 DOI: 10.1007/s40259-019-00402-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Alsamil AM, Giezen TJ, Egberts TC, Doevendans E, Leufkens HG, Gardarsdottir H. Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: a 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106227] [Reference Citation Analysis]
2 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel) 2021;14:189. [PMID: 33669108 DOI: 10.3390/ph14030189] [Reference Citation Analysis]
3 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Macaluso FS, Cummings JF, Atreya R, Choi J, Orlando A. A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. Expert Opin Biol Ther 2021. [PMID: 34314284 DOI: 10.1080/14712598.2021.1958778] [Cited by in F6Publishing: 1] [Reference Citation Analysis]